HYFTHYFTHealthcare · Biotechnology

HYFT Stock Forecast: MindWalk Holdings Corp. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$1.35
+4.65% on the day

The 3 Wall Street analysts covering MindWalk Holdings Corp. hold a median 12-month price target of $5 — +270.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$60.6M
Ticker Nerd rank
59 / 100
Median analyst target
$5.00
Analysts covering
3
Total return, dividends reinvested
1W
−6.2%
1M
−14.0%
YTD
−25.8%
1Y
−17.7%
From 52W high
−57.8%
From 52W low
+32.4%
$1.02
$3.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HYFT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MindWalk Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
84
Size
80
Issuance
79
Momentum
58
Growth
54
Quality
48
Value
43
Revisions
27
Volatility
21

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (21): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own MindWalk Holdings Corp. — and when they’d sell — is the membership.

Wall Street

HYFT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HYFT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26HYFTHigh $5.00Median $5.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.00Median $5.00High $5.00

The green dot is the last close — the median target sits +270.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 May 2026HC Wainwright & Co.ReiteratesBuy$5.00
16 Apr 2026Jones TradingInitiatesBuy

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

HYFT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

MindWalk Holdings Corp. (HYFT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.2×

Cheaper than 89% of US stocks

Price / sales
3.9×

Cheaper than 32% of US stocks

Price / book
7.2×

Cheaper than 14% of US stocks

EV / EBITDA
−3.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
49.8%

Higher than 87% of US stocks

Earnings growth (YoY)
−41.1%

Higher than 12% of US stocks

Gross margin
60.6%

Higher than 75% of US stocks

Operating margin
−105.2%

Higher than 14% of US stocks

Net margin
−89.7%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−85.4%

Higher than 15% of US stocks

Return on assets
−28.4%

Higher than 15% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HYFT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HYFTMindWalk Holdings Corp.$60.6M
59
XLOXilio Therapeutics, Inc.$59.9M
60
PMVPPMV Pharmaceuticals, Inc.$58.8M
66
RNTXRein Therapeutics, Inc.$63.1M
44
CINGCingulate, Inc.$63.6M
19
ACRVAcrivon Therapeutics, Inc.$64.2M
60
PLRXPliant Therapeutics, Inc.$64.4M
79
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HYFT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

FAQ

Frequently asked questions about HYFT stock

What is the HYFT stock price forecast for 2026-2027?

The 3 Wall Street analysts covering MindWalk Holdings Corp. have a median 12-month price target of $5, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HYFT stock a buy right now?

Of the 3 analysts covering MindWalk Holdings Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MindWalk Holdings Corp. 59 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HYFT?

As at 1 Aug 2026, MindWalk Holdings Corp. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will HYFT stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +270.4% from the last close, and Ticker Nerd's factor model ranks MindWalk Holdings Corp. 59 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HYFT stock forecast for 2030?

No analyst covering MindWalk Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HYFT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.

How has HYFT stock performed over the past year?

MindWalk Holdings Corp. returned -17.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MindWalk Holdings Corp. do?

MindWalk Holdings Corp. operates as a bio-native AI company.

Company

About MindWalk Holdings Corp.

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.

CEO Dr. Jennifer Lynne Bath Ph.D. · 74 employees · United States · https://www.mindwalkai.com